Blog Layout

The Role of HealthTech in Enhancing Patient Engagement and Compliance

July 28, 2024

Patient engagement and compliance are critical components of effective healthcare delivery. Engaged patients are more likely to adhere to treatment plans, make informed health decisions, and maintain healthier lifestyles. Compliance with medical advice and prescribed treatments significantly influences patient outcomes, reducing the risk of complications and improving overall health.

HealthTech innovations are playing a transformative role in enhancing patient engagement and compliance. Technologies such as mobile health apps, telemedicine, wearable devices, and AI-driven solutions are creating new opportunities for patients to interact with healthcare providers and manage their health proactively. This blog aims to explore how these HealthTech advancements are improving patient engagement and compliance and to analyze the investment potential in patient-centric health technologies.

Understanding Patient Engagement and Compliance

Patient engagement refers to the involvement of patients in their own healthcare, encompassing actions like actively participating in medical decisions, adhering to prescribed treatments, and maintaining communication with healthcare providers. Compliance, on the other hand, is the extent to which patients follow medical advice and adhere to prescribed treatments.

Engagement and compliance are crucial for achieving optimal health outcomes. Patients who are engaged are more likely to understand their health conditions, follow treatment plans, and take preventive measures, leading to better management of chronic diseases and fewer hospitalizations. However, achieving high levels of patient engagement and compliance remains challenging due to factors such as lack of education, motivation, and access to resources.

HealthTech Innovations in Patient Engagement

HealthTech solutions are designed to address these challenges by providing patients with tools that facilitate better communication, education, and self-management.

Mobile Health Apps

Mobile health apps are revolutionizing patient engagement by providing easy access to health information, reminders for medication, and platforms for tracking health metrics. These apps enable patients to set health goals, monitor progress, and receive personalized recommendations. Features such as push notifications, educational content, and real-time communication with healthcare providers enhance patient involvement and accountability.

For example, apps like MyFitnessPal and HealthifyMe provide comprehensive platforms for diet and exercise tracking, helping users set goals, monitor their progress, and stay motivated. Similarly, medication reminder apps like Medisafe send alerts to patients to take their medications on time, reducing the risk of missed doses and enhancing adherence.

Telemedicine

Telemedicine has become a vital tool for improving patient-provider communication and engagement. It allows patients to consult with healthcare professionals remotely, reducing the need for travel and making healthcare more accessible. Telemedicine platforms facilitate continuous monitoring, follow-up consultations, and timely interventions, thereby enhancing patient engagement and compliance.

During the COVID-19 pandemic, telemedicine platforms such as Teladoc and Amwell experienced a significant surge in usage. These platforms enabled patients to receive medical consultations from the safety of their homes, ensuring continuity of care and minimizing exposure to the virus. By providing a convenient and efficient way to access healthcare, telemedicine has become an essential component of patient engagement strategies.

Wearable Devices

Wearable devices, such as fitness trackers and smartwatches, provide real-time monitoring of vital signs and physical activity. These devices encourage patients to stay active and make healthier choices by tracking their progress and providing instant feedback. Wearables also enable healthcare providers to monitor patients remotely, ensuring timely adjustments to treatment plans and enhancing compliance.

Devices like Fitbit and Apple Watch offer features such as heart rate monitoring, sleep tracking, and activity logging, empowering users to take control of their health. By integrating with mobile health apps, these wearables provide a holistic view of the user's health and facilitate personalized health recommendations.

Patient Portals

Patient portals are secure online platforms that give patients access to their medical records, test results, and personalized health information. These portals enable patients to communicate with their healthcare providers, schedule appointments, and refill prescriptions. By providing easy access to health information and facilitating communication, patient portals enhance engagement and compliance.

Systems like MyChart and Patient Gateway provide patients with a comprehensive view of their health history and ongoing treatments. Patients can review their lab results, request prescription refills, and message their doctors directly through these portals, fostering a more informed and engaged patient population.

HealthTech Innovations in Patient Compliance

Improving patient compliance with treatment plans is essential for achieving desired health outcomes. HealthTech solutions offer innovative ways to support patients in adhering to their prescribed regimens.

Medication Adherence Tools

Medication adherence tools, such as smart pill bottles and reminder apps, help patients remember to take their medications on time. These tools can send alerts to patients and caregivers, track medication intake, and provide refill reminders. Automated alerts and tracking systems ensure that patients adhere to their treatment plans, reducing the risk of complications and improving health outcomes.

For instance, AdhereTech's smart pill bottles send real-time reminders and notifications to patients' smartphones if they miss a dose. These bottles also collect data on medication adherence, which can be shared with healthcare providers to monitor patient compliance and intervene if necessary.

Remote Patient Monitoring

Remote patient monitoring involves the use of digital technologies to track patients' health conditions outside of traditional clinical settings. Devices such as blood pressure monitors, glucose meters, and pulse oximeters transmit data to healthcare providers, allowing for continuous monitoring and timely interventions. Remote monitoring ensures that patients adhere to their treatment plans and enables healthcare providers to make data-driven decisions.

Companies like Livongo offer remote monitoring solutions for chronic conditions such as diabetes and hypertension. These platforms provide patients with connected devices that automatically upload health data to a secure cloud, where it is analyzed and used to provide personalized feedback and support.

AI and Data Analytics

AI and data analytics play a crucial role in developing personalized treatment plans and predictive compliance models. By analyzing patient data, AI algorithms can identify patterns, predict potential adherence issues, and provide tailored recommendations. Predictive analytics help healthcare providers intervene early, improving patient compliance and outcomes.

For example, Propeller Health uses AI to analyze data from connected inhalers and predict asthma attacks before they occur. By providing patients with personalized insights and reminders, the platform helps improve medication adherence and prevent exacerbations.

Behavioral Health Tools

Behavioral health tools, such as gamification and motivational incentives, are designed to encourage patients to adhere to their treatment plans. These tools use game-like elements, rewards, and social support to motivate patients to engage in healthy behaviors and follow medical advice. By making health management more engaging and rewarding, these tools enhance compliance and overall well-being.

Platforms like Mango Health use gamification to encourage medication adherence by rewarding users with points and badges for taking their medications on time. These rewards can be redeemed for real-world incentives, such as gift cards or charitable donations, providing additional motivation for patients to stay compliant.

Notable Labs: Pioneering HealthTech Innovations for Enhanced Patient Engagement and Compliance

Notable Labs is at the forefront of integrating cutting-edge health technologies to significantly improve patient engagement and compliance. By leveraging advanced genetic and molecular analyses, Notable Labs collaborates with healthcare providers to create personalized treatment plans that are both effective and patient-centric. Their commitment to evidence-based practices and robust clinical data supports the development of innovative health solutions that make personalized healthcare accessible and affordable. Notable Labs exemplifies the transformative potential of HealthTech, setting new standards for patient care and ensuring that every patient receives the most tailored and effective treatments possible.

Case Studies of HealthTech Solutions

Case Study 1: Mobile Health App Improving Diabetes Management

A mobile health app designed for diabetes management provides patients with tools to track their blood glucose levels, monitor their diet, and set reminders for medication. The app also offers educational content and real-time communication with healthcare providers. Patients using the app reported improved glycemic control, increased adherence to treatment plans, and higher levels of engagement in their healthcare.

Case Study 2: Telemedicine Platform Enhancing Chronic Disease Care

A telemedicine platform for chronic disease management enables patients to have regular virtual consultations with their healthcare providers. The platform includes features for remote monitoring, medication reminders, and personalized care plans. Patients with chronic conditions, such as hypertension and heart disease, experienced better management of their conditions, reduced hospitalizations, and higher satisfaction with their care.

Case Study 3: Wearable Device Boosting Physical Activity and Adherence to Exercise Plans

A wearable fitness tracker equipped with sensors for monitoring physical activity, heart rate, and sleep patterns helped patients adhere to their exercise plans. The device provided real-time feedback, goal-setting features, and social support through an online community. Users reported increased physical activity, improved fitness levels, and higher adherence to prescribed exercise regimens.

Benefits of Enhanced Patient Engagement and Compliance

Improved Health Outcomes and Quality of Life for Patients

HealthTech solutions that enhance patient engagement and compliance lead to better health outcomes. Patients who actively participate in their healthcare are more likely to follow treatment plans, make informed decisions, and adopt healthier lifestyles. This results in better management of chronic diseases, reduced complications, and improved overall health.

Reduced Healthcare Costs through Prevention and Early Intervention

Engaged and compliant patients are less likely to experience severe health issues that require costly treatments and hospitalizations. By preventing complications and enabling early intervention, HealthTech solutions contribute to significant cost savings for healthcare systems and patients.

Enhanced Patient Satisfaction and Trust in the Healthcare System

When patients are engaged and receive personalized care, they are more satisfied with their healthcare experience. HealthTech solutions that facilitate communication, provide easy access to health information, and support self-management foster trust and confidence in the healthcare system.

Better Data Collection and Insights for Healthcare Providers

HealthTech solutions generate valuable data on patient behaviors, treatment adherence, and health outcomes. This data helps healthcare providers gain insights into patient needs, monitor treatment effectiveness, and make data-driven decisions. Improved data collection enhances the overall quality of care and supports continuous improvement.

Challenges and Risks

Potential Challenges and Risks in Implementing HealthTech Solutions

Despite the numerous benefits, implementing HealthTech solutions for patient engagement and compliance comes with challenges. Technical issues, user adoption, and integration with existing healthcare systems can pose significant hurdles.

Regulatory and Compliance Hurdles

HealthTech solutions must comply with stringent regulatory requirements to ensure patient safety and data privacy. Navigating these regulations can be complex and time-consuming, potentially delaying the implementation of innovative solutions.

Data Privacy and Security Concerns

With the increasing use of digital health technologies, ensuring the privacy and security of patient data is paramount. HealthTech solutions must implement robust security measures to protect sensitive information from breaches and cyber threats.

Strategies for Overcoming These Challenges

To overcome these challenges, HealthTech companies should prioritize user-friendly designs, invest in robust cybersecurity measures, and collaborate with regulatory bodies to ensure compliance. Engaging patients in the development process and providing adequate training and support can also enhance user adoption.

Investment Opportunities in Patient-Centric Health Technologies

Identifying Promising HealthTech Companies and Platforms

Investors should focus on HealthTech companies and platforms that demonstrate a strong commitment to patient engagement and compliance. Companies with a track record of innovation, user-centric designs, and proven outcomes are likely to offer the best investment opportunities.

Factors to Consider When Investing in This Field

When evaluating investment opportunities, consider factors such as the scalability of the solution, regulatory compliance, market demand, and the company's financial health. Additionally, assessing the potential for partnerships with healthcare providers and payers can provide insights into the long-term viability of the investment.

Long-term vs. Short-term Investment Strategies

Both long-term and short-term investment strategies can be effective in the HealthTech sector. Long-term investments allow for the growth and maturation of innovative solutions, while short-term investments can capitalize on emerging trends and early successes.

Examples of Recent Investments and Their Outcomes

Recent investments in HealthTech companies focused on patient engagement and compliance have shown promising outcomes. For example, investments in telemedicine platforms and remote monitoring solutions have yielded significant returns as these technologies became essential during the COVID-19 pandemic.

Future Trends and Innovations

Emerging Trends and Future Directions in HealthTech for Patient Engagement and Compliance

Emerging trends in HealthTech for patient engagement and compliance include the integration of AI and machine learning, the use of virtual and augmented reality for patient education, and the expansion of telehealth services. These innovations promise to further enhance patient care and engagement.

The Impact of Technological Advancements on Patient-Centric Healthcare

Technological advancements such as 5G connectivity, blockchain for secure data management, and advanced wearables will continue to drive innovation in patient-centric healthcare. These technologies will enable more seamless and efficient care delivery, improving patient outcomes.

Predictions for the Next Decade in HealthTech for Patient Engagement and Compliance

Over the next decade, HealthTech solutions will become more personalized, predictive, and preventive. AI-driven analytics will enable proactive interventions, and patient-centric platforms will empower individuals to take control of their health. The integration of HealthTech into everyday life will become more seamless, leading to a more engaged and healthier population.

Conclusion

Recap of Key Points Discussed

HealthTech innovations are transforming patient engagement and compliance, leading to improved health outcomes, reduced healthcare costs, and enhanced patient satisfaction. Technologies such as mobile health apps, telemedicine, wearable devices, and AI-driven solutions are providing patients with tools to manage their health proactively.

Final Thoughts on the Potential of HealthTech in Enhancing Patient Engagement and Compliance

The potential of HealthTech in enhancing patient engagement and compliance is immense. By empowering patients to take an active role in their healthcare, these technologies can significantly improve health outcomes and quality of life. Continued investment in innovative HealthTech solutions is essential to realize this potential fully.

Encouragement to Support and Invest in Patient-Centric HealthTech Solutions

Investing in HealthTech solutions focused on patient engagement and compliance is not only financially rewarding but also socially impactful. By supporting these innovations, investors can contribute to a healthier, more efficient healthcare system that benefits patients and providers alike.

< Older Post Newer Post >

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024

Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.

A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024

Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.

A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024

Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.

A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024

Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.

A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024

Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.

A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024

Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.

Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024

Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.

A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024

Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.

A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024

Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.

A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024

Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial. Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.